New Head to Head Phase 3 study evaluated the reduction of systolic blood pressure of an experimental compound Azilsartan medoxomil compared with valsartan

At 24 weeks, azilsartan medoxomil 40 mg / day and 80 mg / day reduced the mean 24 hour ABPM of 14.9 mmHg and 15.3 mmHg, base. The reductions were statistically significantly higher than those observed with valsartan 320 mg / day . Even at 24 weeks, azilsartan medoxomil 40 mg / day and 80 mg / day reduces Bowl clinical measurement of systolic blood pressure from 14.9 mmHg and 16.9 mmHg, base. The reductions were statistically significantly higher than those observed with valsartan 320 mg / day Takeda Global Research & Development Center, Inc. The results showed that azilsartan medoxomil reduced 24-hour SBP average ambulatory blood pressure monitoring , the primary endpoint, and SBP in a clinical study of head-on -one with the highest approved dose of valsartan in hypertensive patients. The results of the study were statistically significant and were presented at the European Society of Hypertension Annual Scientific Meeting in Oslo, Norway.

Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Discovered by Takeda, azilsartan medoxomil, also known as TAK-491, an inhibitor of angiotensin II in development for the treatment of hypertension, or high blood pressure, alone or in combination with other classes of antihypertensive drugs. Angiotensin II, a vasopressor, is a hormone that occurs naturally in the body and plays a key role in cardiovascular function. The hormone induces contraction or narrowing of blood vessels and thus plays an important role in mediating hypertension. The most frequently reported treatment-related adverse reactions in Phase 3 clinical trials were dizziness and diarrhea .

The new drug application azilsartan medoxomil was made to the Food and Drug Administration in April 2010 and was supported by seven phase 3 clinical trials involving over 5900 patients.1 percent), increased blood creatine phosphokinase and .

Headquartered in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. Their respective companies currently market oral rheumatology and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions.

‘Control continues to be a serious problem with over half of these patients do not reach their blood pressure,’ said Domenico Sica, MD, principal investigator and professor of internal medicine and nephrology at Virginia Commonwealth University Medical Center.

‘We were encouraged by the results, which showed a greater reduction in blood pressure observed in patients treated with azilsartan medoxomil compared to valsartan, and believe that the compound, if approved, may be important treatment option to help patients control the their hypertension. ‘